Updates

Statement on U.S. Settlement Program

Friday, February 20, 2015

DePuy and the Court-appointed committee of lawyers representing ASR™ Hip System plaintiffs have reached an agreement to effectively extend the benefits of the existing U.S. Settlement Program to include eligible ASR patients in the U.S. who had surgery to replace their ASR hip after August 31, 2013, and on or before January 31, 2015. The existing U.S. Settlement Program was announced in November 2013 and has compensated eligible ASR patients in the U.S. who had surgery to replace their ASR hip as of August 31, 2013.

Statement Regarding ASR Hip System Verdict in Tulsa, OK

Tuesday, February 3, 2015

A jury returned a mixed verdict today in a trial concerning the ASR™ Hip System in the Tulsa County District Court, Civil Division. The jury found that the ASR XL was defectively designed. The jury also found that DePuy was not negligent and properly informed the plaintiff’s physician of the known risks associated with ASR XL.
“We believe ASR XL was properly designed, and that DePuy’s actions concerning the product were appropriate and responsible,” said Mindy Tinsley, a spokeswoman for DePuy. “We plan to appeal the jury’s decision on design defect.”

DePuy Announces U.S. Settlement Agreement to Compensate ASR™ Hip System Patients Who Had Surgery to Replace Their ASR Hip

Tuesday, November 19, 2013

DePuy Orthopaedics, Inc. (DePuy) and the Court-appointed committee of lawyers representing ASR™ Hip System plaintiffs today announced a settlement agreement to compensate eligible ASR patients in the United States who had surgery to replace their ASR hip, known as revision surgery, as of August 31, 2013.

Statement Regarding ASR Hip System Verdict in Chicago, IL

Friday, August 16, 2013

A jury in the Circuit Court of Cook County, Illinois, returned a verdict today in favor of DePuy Orthopaedics Inc. in a product liability lawsuit concerning the ASR™ Hip System.

“DePuy’s actions concerning the product were appropriate and responsible, including the program to address patients’ medical costs related to the recall,” said Lorie Gawreluk, a spokeswoman for DePuy.

For additional information on the ASR Hip System, please visit: www.ASRHipInfo.com.

ASR Hip System Recall Information

Recall of hip replacement system was the right decision at the right time

Monday, March 25, 2013

When DePuy, a Johnson & Johnson company, decided to recall the Articular Surface Replacement (ASR) Hip System in August 2010, it was the right decision at the right time.

Only at that point did new data from a United Kingdom national joint registry report that 13% of patients were undergoing a second hip replacement surgery, called revision surgery, sooner than expected. We immediately recalled the product in every country where it was sold.

Statement Regarding ASR Hip System Verdict in Los Angeles, CA

Friday, March 8, 2013

In the first ASR™ Hip System case to go to trial in the United States, a jury in the California Superior Court, Los Angeles County, returned a mixed verdict after a five week trial. The jury found that the ASR XL was defectively designed. The jury rejected the plaintiff’s claim that DePuy Orthopaedics, Inc. failed to adequately warn of the risks associated with ASR XL.

“We believe ASR XL was properly designed, and that DePuy’s actions concerning the product were appropriate and responsible,” said Lorie Gawreluk, a spokeswoman for DePuy. “We plan to appeal the jury’s decision on design defect pending the outcome of post-trial motions. We believe we have a number of valid grounds for appeal, notably that the court didn’t let the company tell the jury about the Food and Drug Administration’s review and clearance of the device.”

The jury rejected plaintiff’s claim for punitive damages and awarded $8,338,000 in compensatory damages.

Letter to the Editor from DePuy Published in the New York Times

Monday, March 25, 2013

To the Editor:

Re “What a Company Knew About Its Metal Hips” (editorial, Feb. 11):

All of us at DePuy are united by the goal of improving patients’ lives, so we understand that the Articular Surface Replacement Hip System recall has been of concern for patients, their family members and surgeons. I disagree with how your editorial described company actions regarding ASR testing, data analysis and communications.